To build a high‑standard core technology platform for cell therapy processes, from May 20 to June 15, the technical team of Sedate Biotechnology visited Shanghai Tofflon Science and Technology Group to conduct in‑depth customized validation and system integration testing for the core equipment of Sedate’s innovative CGT laboratory.

This validation focused on highly customized equipment development and adaptation to cutting‑edge technologies. Based on the project‑specific process flows and high‑level user requirements, the technical team performed comprehensive technical matching and performance verification on the key equipment manufactured by Tofflon, ensuring that every step met or even exceeded the preset technical specifications. This fully demonstrates the forward‑looking and leading nature of the laboratory equipment system in the CGT field.

With the completion of this phase, the series of customized advanced equipment will move into the on‑site installation and integration stage. Subsequently, Sedate Biotechnology will steadily advance the construction of the laboratory and supporting production systems, accelerating the full‑chain integration from engineering breakthroughs to clinical translation.

Sedate’s innovative CGT laboratory carries the company’s strategic mission of overcoming key technical barriers in the CGT field and driving the industrial implementation of cutting‑edge biotechnologies. Among these, the highly customized core production equipment serves as the critical infrastructure that supports this high‑barrier platform in moving from laboratory research to industrial‑scale application.